FDA Approves Investigational New Drug for Neuroendocrine Tumors
FDA approves Investigational New Drug (IND) that enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE (177Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors (NET)